Telix Pharmaceuticals Limited
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-7.1M | $33.7M | $4.2M |
| Depreciation & Amortization | — | — | — |
| Depreciation | $3.7M | $774.0K | — |
| Amortization | $9.9M | $3.1M | — |
| Stock-Based Compensation | $19.1M | $12.9M | $5.8M |
| Net Cash from Operating Activities | $-17.3M | $27.5M | $14.3M |
| Investing Activities | |||
| Capital Expenditures | $25.7M | $9.1M | $6.3M |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-285.9M | $-86.7M | $-16.8M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $-3.7M | $416.8M | $7.1M |
| Net Change in Cash | — | — | — |
| Free Cash Flow | $-43.0M | $18.4M | $8.0M |